Bayer Aktie
18,81 EUR -0,20 EUR -1,03 %
STU
Werbung
Bayer Rating
Bayer Aktie Moody's Rating
Baa2
C
A3
Aaa
Investmentwürdig - Hohe Sicherheit
Investmentwürdig - Mittlere Sicherheit
Nicht als Investment geeignet
Investmentwürdig - Mittlere Sicherheit
Nicht als Investment geeignet
| Rating | Baa2 | Rating Typ Bank Financial Strength Rating Insurance Financial Strength Rating Enhanced Rating Insured Rating Long-Term Bank Deposit Rating Long-Term OSO Rating Long-Term Debt Rating Money Market Fund Rating Modeled Shadow Rating Management Quality Rating Probability of Default Rating Pfd/Pref Stock Rating Prospective Pfd/Pref Rating Short-Term Bank Deposit Rating Speculative Grade Liquidity Rating Prospective LT Debt Rating Short-Term Insurance Financial Strength Rating Short-Term OSO Rating Servicer Quality Short-Term Debt Rating Lloyd´s Syndicate Performance Rating Underlying Rating Unknown - for conversion use only | Long-Term Debt Rating |
| Letzte Aktion | AFFIRM | Moody's Büro in | - |
Anleihen von Bayer mit Moody's Ratings
| Emittent | Anzahl Anleihen | Ratings |
|---|---|---|
| Bayer AG | 18 | Ba1, Baa2, Baa3 |
| Bayer Capital Corp. B.V. | 2 | Baa2 |
Moody's Ratings Peer Group
| Aktie | Rating |
|---|---|
| Abbott Laboratories | Aa3 |
| Amgen Inc. | Baa1 |
| AstraZeneca PLC | A2 |
| BASF | A3 |
| Bayer | Baa3 |
| Biogen Inc | Baa2 |
| Celgene Corp. | A3 |
| DSM NV | A3 |
| Henkel KGaA Vz. | A2 |
| Johnson & Johnson | Aaa |
| LANXESS AG | Baa3 |
| Merck Co. | A1 |
| Merck KGaA | A3 |
| Merck KGaA | Baa1 |
| Pfizer Inc. | A1 |
| Pfizer Inc. | A2 |
| Sanofi S.A. | A1 |